The Chief Executive of Bristol-Myers Squibb Co said the company intends to remain “100 percent” in prescription medicines and is prepared to use its $10 billion cash hoard to gain new drugs through moderate size deals with other drugmakers. Lamberto Andreotti also told scores of industry executives and analysts that the company’s recently approved Yervoy medicine for metastatic melanoma continues to generate good initial sales. “We will continue to remain 100 percent pharma,” Andreotti said at the Pharmaceutical Strategic Alliances Conference in New York. He said it was beneficial to have “the entire management team strictly focused on one business.”
